Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses.

Bill Gates's comments on genetics as "code" have reignited debate over genetic engineering, intellectual property, and the ...

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.

Scientists are venturing into the realm of de-extinction, aiming to revive the woolly mammoth using advanced genetic ...

For centuries, extinction has meant the end—but what if it didn’t have to? Using advanced genetic engineering, a handful of ...

Advances in genome editing are transforming the treatment for rare genetic diseases, as seen in the case of seven-month-old ...

The global regenerative medicine market is poised for remarkable expansion, expected to record a compound annual growth rate (CAGR) of around 17% during the forecast period. This surge is primarily ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

Overview of Whole Genome Synthesis MarketThe global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics ...

NLS Pharmaceutics Ltd. ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. ("Kadimastem"), a clinical-stage ...